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ABSTRACT
Background. Mechanical ventilation for acute respiratory failure is one of the most
common indications for admission to intensive care units (ICUs). Airway mucus
clearance is impaired in these patients medication, impaired mucociliary motility,
increased mucus production etc. and mucoactive agents have the potential to improve
outcomes. However, studies to date have provided inconclusive results. Despite this
uncertainty, mucoactives are used in adult ICUs, although the extent of use and
perceptions about place in therapy are not known.
Aims and Objectives. We aim to describe the use of mucoactive agents in mechanically
ventilated patients in UK adult critical care units. Specifically, our objectives are to
describe clinicians perceptions about the use of mucoactive agents, understand the
indications and anticipated benefits, and describe the prevalence and type ofmucoactive
agents in use.
Methods. We conducted three surveys. Firstly, a practitioner-level survey aimed at
nurses, physiotherapists and doctors to elucidate individual practitioners perceptions
about the use of mucoactive agents. Secondly, a critical care unit-level survey aimed
at pharmacists to understand how these perceptions translate into practice. Thirdly,
a point prevalence survey to describe the extent of prescribing and range of products
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in use. The practitioner-level survey was disseminated through the UK Intensive Care
Society for completion by a multi-professional membership. The unit-level and point
prevalence surveys were disseminated cthrough the UK Clinical Pharmacy Association
for completion by pharmacists.
Results. The individual practitioners survey ranked ‘thick secretions’ as the main
reason for commencing mucoactive agents determined using clinical assessment. The
highest ranked perceived benefit for patient centred outcomes was the duration of
ventilation. Of these respondents, 79% stated that further research was important and
87% expressed support for a clinical trial. The unit-level survey found that mucoactive
agents were used in 83% of units. The most highly ranked indication was again
‘thick secretions’ and the most highly ranked expected patient centred clinical benefit
being improved gas exchange and reduced ventilation time. Only five critical care
units provided guidelines to direct the use of mucoactive agents (4%). In the point
prevalence survey, 411/993 (41%) of mechanically ventilated patients received at least
one mucoactive agent. The most commonly administered mucoactives were inhaled
sodium chloride 0.9% (235/993, 24%), systemic carbocisteine (161/993, 16%) and
inhaled hypertonic sodium cloride (127/993, 13%).
Conclusions. Mucoactive agents are used extensively in mechanically ventilated adult
patients in UK ICUs to manage ‘thick secretions’, with a key aim to reduce the duration
of ventilation. There is widespread support for clinical trials to determine the optimal
use of mucoactive agent therapy in this patient population.
Subjects Drugs and Devices, Emergency and Critical Care, Pharmacology, Respiratory Medicine
Keywords Acute respiratory failure, Mechanical ventilation, Mucoactive agents
INTRODUCTION
Patients admitted to critical care frequently have acute respiratory failure and often require
ventilation (Narendra et al., 2017;Vincent et al., 2002). Acute respiratory failure (ARF)may
be due to a neuromuscular issue, secondary to an acute exacerbation of chronic obstructive
pulmonary disease (COPD), an alveolar process (e.g. cardiogenic and noncardiogenic
pulmonary oedema and pneumonia) or a vascular disease such as pulmonary embolism
(MacSweeney, McAuley & Matthay, 2011). Large numbers of patients receive respiratory
support in ICUs with an estimated 116,000 adult admissions in the UK alone for respiratory
support every year (Harrison, 2014).
Ventilatory support and the requisite associated medications such as analgesics and
sedatives are essential medical interventions that can affect other physiological mechanisms
andmayworsen them (Jelic, Cunningham & Factor, 2008).Mucus production and rheology
is altered, andwhen combinedwith the diminished effectiveness of cough reflexes, impaired
mucociliary clearance and the influence of gravity and body positioning on mucus flow,
lead to mucus accumulation and plugging. The accumulation of mucus may also facilitate
the growth of microorganisms, leading to infection (Mietto et al., 2013; Kalanuria, Zai &
Mirski, 2014; Icard & Rubio, 2017; Konrad et al., 1994; Dickson, 2016).
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The role of mucoactive agents is established in various chronic respiratory
conditions such as COPD and cystic fibrosis where several therapeutic agents are
used as aids to mucus clearance. These agents are administered either topically
(inhaled/nebulised/intratracheal instillation) such as hypertonic sodium chloride solutions
and recombinant deoxyribonuclease, or systemically such as carbocisteine (Tarrant
et al., 2017; Wark & McDonald, 2018; Yang & Montgomery, 2018; Cazzola et al., 2017).
The available literature regarding mucoactive agent use in critically ill patients with
acute respiratory failure suggests widespread but inconsistent practice in the context of
limited evidence (Jelic, Cunningham & Factor, 2008; Papacostas, Luckett & Hupp, 2017;
Van Meenen et al., 2018; Anand et al., 2019; Icard & Rubio, 2017).
There are no published data on the use of mucoactives in UK critical care units. In order
to gain as comprehensive an insight as possible, we conducted three surveys to explore
various aspects of UK practice:
Survey 1 aimed to characterise how individual practitioners view the use of mucoactive
agents (practitioner-level survey);
Survey 2 aimed to explore which mucoactive agents are used across adult UK critical
care units and discover the extent of guideline use (unit-level survey);
Survey 3 aimed to determine the actual usage pattern of various mucoactive agents
currently in clinical use (point prevalence survey).
MATERIALS & METHODS
Survey questions were developed and prepared in Survey Monkey (Survey Monkey Inc,
San Mateo, California, USA) for the practitioner-level and unit-level surveys. A data
capture tool for the point prevalence survey was developed in Excel (Microsoft Excel 2010,
Redmond, WA, USA). All survey instruments were piloted and iteratively refined.
The practitioner-level survey was distributed to the membership of the UK Intensive
Care Society (ICS) via a newsletter on 17 September 2018. Responses were collected until
8th January 2019. Reasons for mucoactive agent use were collected by asking respondents
to rank a list of clinical conditions and indications (see supplementary appendix).
Due to familiarity with medicines practice amongst multiple prescribers across critical
care environments, pharmacists were targeted as respondents of choice to report unit-level
and point prevalence surveys (Intensive Care Society & Faculty of Intensive Care Medicine,
2019).
For the unit-level survey, respondents were asked to rank unit practice regarding
indications and anticipated benefits of mucoactive agents, to specify which agents are in
use, and to provide copies of any guidelines used. Invitations to participate, including
the survey link, were distributed electronically to UK critical care pharmacists via the UK
Clinical Pharmacy Association. Responses were collected from 4th April 2018 to 25th April
2018.
For the point prevalence survey, the Excel tool was circulated electronically to all the
pharmacists via the UK Clinical Pharmacy Association. Participants were requested to
collect data for one 24 h period of their choosing for each critical care unit between the
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18th March 2019 and 23rd April 2019. Additional forward distribution to further critical
care pharmacy contacts was requested. To encourage survey participation, reminders that
including response rate statistics were circulated at regular intervals via email or Twitter
until the surveys closed. Only one survey response for each unit was allowed.
The survey questionnaires are attached as an online supplement.
The denominator for UK critical care units was defined as the number of units
participating in the Intensive Care National Audit and Research Centre Case Mix
Programme (England, Wales, Northern Ireland, n= 276) and Scottish Intensive Care
Society Audit Group (n= 63).
Response data from Survey Monkey were downloaded to Excel (Microsoft Office, WA,
USA) for analysis. Ranked data were converted into Borda counts for comparison. Briefly,
this method assigns a score to each choice made, depending on the ranked position. The
total score for each category is calculated by summation of these individual scores. For
example, if there are three choices to rank in a category, each ranked first choice attracts
a score of 3, each ranked second choice attracts a score of 2 and each ranked third choice
attracts a score of 1. All scores are totaled for each category. The higher the score, the higher
the choice is favoured (Emerson, 2013).
Some results of the unit-level survey have been published elsewhere as an abstract
(Borthwick et al., 2019).
RESULTS
Practitioner-level survey
Questionnaires were sent to 3,099 clinician members of the ICS, of whom 225 completed
the survey. The response rate was 8% but represented 37% of UK adult ICUs. Medical
consultants formed the majority of the respondents and followed by medical trainees
(Table 1). The highest proportion of respondents were from a ‘mixed medical/surgical
ICUs (including trauma)’ (86%) followed by ‘other’ (8%). The most highly ranked clinical
indication was ‘thick secretions’, followed by ‘COPD’ (Fig. 1). Except for one respondent,
the assessment of ‘thick secretions’ was always based on clinical observation. Improved
sputum clearance was themost highly ranked perceived benefit frommucoactive use (78%)
while reduced time of mechanical ventilation (14%) was the most highly ranked patient
centred clinical outcome (Fig. 2). A significant majority (79%) of respondents indicated
that further research in the use of mucoactive agents was important and a similarly high
percentage (87%) of respondents expressed their support for a clinical trial. However, a
high proportion of respondents (28%) indicated they would not support a clinical trial
that does not allow topical 0.9% sodium chloride as part of standard care.
Unit-level survey
Pharmacists representing 128/341 critical care units responded (38%; including two
additional units that do not provide data for the ICNARC case mix programme).
Mucoactives were used in 106/128 ICUs (83%). The most highly ranked indication
for mucoactive use was ‘thick secretions’ (Fig. 3). ‘Reduced ventilation time’ was the most
highly ranked expected patient centred clinical outcome, with improvement in gas exchange
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Table 1 Practitioner level survey—breakdown based on professional group.
Professional group Number of responses (%a)
Medical –Consultant 178 (80)
Medical –Trainee 22 (10)
Medical –Other 2 (<1)
Physiotherapist 11 (5)
Nursing 11 (5)
Not available 1 (<1)
Notes.
a% is rounded to the nearest whole number.
Figure 1 Usual indication for mucoactive agents in use.
Full-size DOI: 10.7717/peerj.8828/fig-1
also identified as an important benefit (Fig. 4). The highest ranking mucoactive agents
reportedly in use were topical isotonic saline (ITS) and systemic carbocisteine respectively
(Fig. 5). A wide range of topical hypertonic saline solutions and two concentrations
of topical N-acetylcysteine were also reported (Fig. 5). Only five ICUs provided local
guidelines directing the use of mucoactive agents (4%).
Point prevalence survey
Critical care pharmacists representing 63% of UK critical care units contributed to the
survey and included data from 993 invasively mechanically ventilated patients. 41% of
patients were prescribed one or more mucoactive agents, confirming the wide prevalence
of mucoactive use in mechanically ventilated patients. Excluding isotonic saline, the
prevalence of mucoactive agents in invasively mechanically ventilated patients was 27.1%.
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Figure 2 Expected clinical benefit for mucoactive agents in use.
Full-size DOI: 10.7717/peerj.8828/fig-2
Figure 3 Usual indication for mucoactive agents in use.
Full-size DOI: 10.7717/peerj.8828/fig-3
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Figure 4 Expected clinical benefit for mucoactive agents in use.
Full-size DOI: 10.7717/peerj.8828/fig-4
Figure 5 Topical and systemic mucoactive agents in use.
Full-size DOI: 10.7717/peerj.8828/fig-5
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Table 2 Prevalence and types of mucoactive agents used in UK ICUs—point prevalence survey.
Yes (%) No (%)
Any mucoactive use 411 (41.4) 582 (58.6)
Nebulised/intra-tracheal 0.9% saline 235 (23.7) 758 (76.3)
Systemic carbocisteine 161 (16.2) 832 (83.8)
Nebulised hypertonic saline 127 (12.8) 866 (87.2)
Nebulised/intra-tracheal N-acetylcysteine 38 (3.8) 955 (96.2)
Nebulised DNase 1 (0.001) 992 (99.999)
Nebulised or intra-tracheal isotonic saline, systemic carbocisteine and hypertonic saline
were the threemost frequently usedmucoactive agents in invasivelymechanically ventilated
patients (Table 2). Themost frequent concentration range for hypertonic salinewas 5–7%.
DISCUSSION
This study provides the first detailed description of mucoactive use in mechanically
ventilated patients within critical care in theUK. There are no comparable studies describing
the perceptions and prevalence of mucoactive use in mechanically ventilated ICU patients
globally, hence our study addresses this important knowledge gap.
The unit-level survey shows that mucoactive agents are used in the majority of critical
care units (83%), and the point prevalence survey finds that a high prevalence amongst
mechanically ventilated patients (41%). Given the response rate from the unit level and
point prevalence surveys of up to two-thirds of respondents (38% and 63%), we believe
the results to be generalizable to UK critical care practice.
Mucoactive agents act through a variety of mechanisms, such as decreasing viscosity,
increasing mucus water content and stimulating cough. They may have the potential to
improve patient outcomes in mechanically ventilated patients and could reduce the risk
of secondary bacterial infection (Mietto et al., 2013; Balsamo, Lanata & Egan, 2010). Some
mucoactive agents may also have a direct anti-inflammatory effect (Balsamo, Lanata &
Egan, 2010). Notwithstanding a plausible biological rationale, the evidence for clinically
meaningful beneficial endpoints is conflicting. Recent systematic reviews investigating the
role of mucoactive agents in acute respiratory conditions including mechanically ventilated
patients highlight both the lack of evidence and the low quality of current evidence to
support clinical practice (Tarrant et al., 2017; Papacostas, Luckett & Hupp, 2017; Anand
et al., 2019; Icard & Rubio, 2017). There was no consistent benefit on various clinical
outcomes including duration of mechanical ventilation, duration of ICU stay, mucus
clearance, radiological changes and oxygenation while there is some evidence of harm
(Wong, Anderson & Shyamsundar, 2019). A major limitation of the available data is that
the studies are small and inadequately powered.
A recent largemulti-centre trial of patients undergoingmechanical ventilation has found
‘on demand’ N-acetylcysteine nebules for thick secretions to be non-inferior to routine use
(Van Meenen et al., 2018), but this study had no placebo arm and so any overall benefit of
N-acetylcysteine remains unclear.
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Despite a lack of robust supporting evidence, our study confirms a high prevalence
of mucoactive agent use, with the most common indication for ‘thick secretions’ and
a clinical aim of reducing duration of ventilation. Our study also confirms the high
prevalence of the use of 0.9% sodium chloride through the intratracheal route while the
other common mucoactive agents in use are systemic carbocisteine and topical hypertonic
saline. The clinical benefit of topical mucoactive agents such as nebulised isotonic saline
that exert their action through simple airway humidification is unlikely to be significant in
mechanically ventilated patients though use is common. Future clinical trials of mucoactive
agents should include 0.9% sodium chloride as a component of standard care due to the
very wide prevalence of use, and opposition to any study that does not allow this as part of
standard care.
The strengths of this study are the inclusion of three different surveys that enable
us to understand healthcare professionals’ perception of the indication and benefits of
mucoactive agents, as well as objective evidence of their actual pattern of use. For the first
time, this study clearly establishes the type and range of mucoactive agents used in critical
care in the UK. The response rate for the point prevalence study was more than 60% and is
therefore likely to provide an accurate reflection of clinical practice. The limitations of the
study are that the actual number of respondents for the practitioner-level survey was low
which may limit the generalisability of this aspect, and that the point prevalence survey was
conducted during spring when there could be seasonal variation in the use of mucoactive
agents.
CONCLUSIONS
This study finds that there is a high prevalence of mucoactive agents use in mechanically
ventilated adult patients in the UK in spite of the lack of robust evidence of benefit. The
highest ranked indication to initiate mucoactive agents is thick secretions with duration
of ventilation the patient centred outcome ranked highest for perceived benefit in the
practitioner level and highly in the unit-level survey. There is a need for a well-designed,
adequately powered multicenter trial of commonly used mucoactive agents in patients
that are mechanically ventilated and have thick secretions. There is widespread support for
undertaking such a trial.
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